

PGD Number: **437** Version: 05

PATIENT GROUP DIRECTION FOR THE SUPPLY OF DOXYCYCLINE FOR TREATMENT OF CHLAMYDIA AND NGU, CONTACTS OF CHLAMYDIA OR CONTACTS OF NON-GONOCOCCAL URETHRITIS (NGU) PRESENTING WITH TREATMENT VOUCHER TO COMMUNITY PHARMACISTS

MANAGEMENT OF PATIENT GROUP DIRECTION

This Patient Group Direction must be read, agreed to and signed by all healthcare professionals involved in its use. The original signed copy should be held by a designated person and must be easily accessible to healthcare professionals in the clinical setting. In all cases the healthcare professional will follow the code of conduct as defined by their professional body.

	Name	Signature	/D/ate
Developed by LOCAL DEVELOPMENT	Developed by LOCAL DEVELOPMENT TEAM		
Doctor	Dr Sally Wielding		18/06/25
Practitioner	Michelle Wood		22/05/25
Pharmacist	Garry Todd		22/05/25

Approved by PGD SUB-GROUP OF THE MEDICINES POLICY COMMITTEE			
Chairperson	Jane Browning		28/07/2025
Chairperson	Pat Wynne		28/07/2025

Approved by AUTHORISED NHS LOTHIAN DRUGS AND THERAPEUTICS COMMITTEE			
Chairperson/Deputy of Committee	Dr Emma Morrison		28/07/2025
Chairperson/Deputy of Committee	Scott Garden		28/07/2025
AUTHORISED BY			
Medical Director	Ms Tracey Gillies		28/07/2025

LOCAL MANAGEMENT			
Practice/Ward/Department/Dire	ectorate		
Clinical Lead			
Practitioner Manager (if applica	able)		
Pharmacist (if applicable)			
Name of Designated PGD Hold (Responsible for ensuring names of healthcare professionals issuing under this PGD are kept u			
DATE AUTHORISED FOR USE	REVIEW DATE	EXPIRY DAT	ſΕ
28/07/2025	28/07/2027	28/07/2028	3

NHS Lothian

NHS Lothian Patient Group Direction

PGD Number: **437** Version: 05

Title: Doxycycline: Chlamydia – Sexual Health Services

Contractor Code	
Locum	

AUTHORISED PRACTITIONER LIST: I have read and understood the Patient Group Direction and agree to use it and acknowledge that it is my responsibility to maintain my knowledge, skills and competencies through CPD.			
			Name



nt Group Direction PGD Number: 437 Version: 05

1. CHARACTERISTICS OF STA	FF
Qualifications and Professional Registration	Registered Pharmacist with current GPhC Registration, working in community pharmacy in NHS Lothian, signed up to provide treatment of chlamydia and non-specific gonococcal urethritis via service level agreement.
Qualifications Required	GPhC Registration
Additional requirements	Undertaken Continuing Professional Development (CPD) to ensure understanding of areas related to the pharmacy service in relation to Chlamydia infection
	Online learning/update regularly from Lothian and Reproductive Health services to cover evaluation of Chlamydia and NGU infection and voucher system.
	Understanding of potential complications of Chlamydia infection such as pelvic inflammatory disease, using the checklist and when to refer patients to Lothian sexual and reproductive health services (LSRHS) for further assessment and treatment
	Understanding of how to assess risk of pregnancy in line with the checklist and refer to LSRHS if required
	Undertaken appropriate training for working under PGDs for the supply of medicines .Examples include : NICE competency framework for PGDs Tools and resources Patient group directions Guidance NICE Introduction to PGDs - SPS - Specialist Pharmacy Service - The first stop for professional medicines advice
	Able to assess the person's capacity to understand the nature and purpose of the medication to give or refuse consent
	Basic understanding of public protection guidance including assessing risk factors for Child protection and Adult protection concerns
	Basic understanding of assessing service users under the age of 16
	The TURAS e-learning package on Public Protection (the informed and skilled modules for Adult and Child protection) should be completed The module is available on the NES Portal (https://portal.scot.nhs.uk). The training must be satisfactorily completed as per NES performance indicators by completing the appropriate assessments to a satisfactory standard.
Continued training requirements	Updates on the management of chlamydial infection and non-gonococcal urethritis (NGU) through community pharmacy / LSRH training updates



PGD Number: **437** Version: 05

2. DESCRIPTION OF TREATMEN	NT
Names of Medicines included	Doxycycline
Marketing Authorisation (previously UK Product Licence)	YES
Outwith terms of the Summary of Product Characteristics	NO
2 nd Pharmacist Check	
Controlled Drugs	NO
If YES, consultation with CDGT to check legal compliance	
Antibiotic	
If YES, consultation with Microbiologist/Antimicrobial Management Team	Yes – aligns with local treatment guidelines.
Children under 13 years of age to be treated	NO
If YES, consultation with Neonatologist, Paediatrician, Public Health or Unscheduled Care	
Record / Audit trail	The Patient Medication Record (PMR) system record is used to document when PGD used against patient details/voucher Specific recording requirements as per NHS Lothian: • that valid informed consent was given • name of individual, address, date of birth and GP with whom the individual is registered (if relevant) • name of registered health professional • name of medication supplied/administered • date of supply/administration • dose, form and route of supply/administration • quantity supplied/administered • batch number and expiry date (if applicable) • advice given, including advice given if excluded or declines treatment • details of any adverse drug reactions and actions taken • supplied via Patient Group Direction (PGD) number ———————————————————————————————————



Treatment voucher number/details to be returned to health advisors at NHS Lothian Sexual Health Service Sexual Health for payment processing using a community pharmacy payment claim form
Testing, processing of results and vouchers issued are entered via NASH – Scottish sexual health electronic record system by Lothian sexual health staff / Chalmers Centre

3.1 MEDICINES and CLINICA	L CONDITION
Name of medicine	Doxycycline
Define situation/condition	Uncomplicated Chlamydia infection or non-gonococcal urethritis (NGU)
	Contacts of Chlamydia or NGU infection - asymptomatic
	Pharmacists will be presented with a SMS 'voucher' stating Chlamydia diagnosis or as a named contact. Pharmacy will then assess clinical appropriateness of PGD use using Doxycycline as treatment option. Refer to LSRHS if assessed as not appropriate under PGD criteria. Information and checklist found at
	www.communitypharmacy.scot.nhs.uk/nhs-lothian/pages/patient-group-directions-pgds/
	Vouchers should be checked they are within 14 days of being sent /issued – they expire after 14 days and will need re-instated – refer back to Chalmers Centre – contact details within referral, patient monitoring and follow up section
	The vouchers should state:
	Your Chlamydia test is positive. Attend a pharmacy from this link to collect treatment using the voucher AN00000000: https://bit.ly/3G0ERjJ Before you collect treatment read this checklist: https://www.lothiansexualhealth.scot/sti-testing/chlamydia-voucher/ voucher expires 14 days.
	OR for contacts
	"Attend a pharmacy from this link to collect treatment using the voucher CON/4-digits-index-AN. https://bit.ly/3G0ERjJ before you collect treatment read this checklist: https://tinyurl.com/3jsp7h7y voucher expires 14 days."
	Vouchers should then be deleted within pharmacy premises to avoid duplicate use

PGD Number:

Version:

437

05



Outtoute for to 1	Definition to the Property of
Criteria for inclusion (including patient group)	Patients who have been diagnosed with chlamydia/NGU presenting with a treatment voucher from LSRH services Contacts of patients who have been diagnosed with chlamydia/NGU presenting with a treatment voucher from LSRH services Consent given Aged 13 years and over
Criteria for exclusion	 Known allergy or hypersensitivity to doxycycline, other tetracycline antibiotics or to any component of the product - see Summary of Product Characteristics (SPC) Patient using Interacting medicines listed within the Interactions section are excluded - please refer to Chalmers Centre Patients who will have sun / UV exposure and not able or willing to take preventative measures – please refer to Chalmers Centre for alternative treatment options Consent not given Individuals under 13 years of age Individuals under 16 years old and assessed as lacking capacity to consent using the Fraser Guidelines Individuals 16 years of age and over and assessed as lacking capacity to consent. Actual or suspected pregnancy Breastfeeding Renal or hepatic impairment Systemic lupus erythematosus Myasthenia gravis Acute porphyria Individuals with oesophagitis swelling of the lymph nodes swelling or pain at the anus recent pain in your lower abdomen pain inside the vagina when having vaginal sex pain inside the anus when having anal sex abnormal or unscheduled bleeding from the vagina or anus a high temperature or you feel very unwell Termination of pregnancy within the last 4 weeks Intra-uterine contraceptive device (a coil) inserted in the last 4 weeks Patients are asked to refer to online checklist prior to attending local pharmacy for treatment and to contact Chalmers centre if do not fit criteria www.lothiansexualhealth.scot/sti-testing/chlamydia-voucher/

PGD Number:

Version:

437 05



PGD Number: 437 Version: 05

Action if excluded Action if patient declines	Advise to contact either NHS Lothian Sexual Health Service or patient's own GP Chalmers Centre 2a Chalmers Street 0131 536 1070/2108 Contact NHS 24 / 111 if symptoms urgent / concerning Follow local guidelines for management of Public / Child protection concerns Advise to contact either NHS Lothian Sexual Health Service or patient's own GP Chalmers Centre 2a Chalmers Street 0131 536 1070/2108
	Contact NHS 24 / 111 if symptoms urgent / concerning
Pharmaceutical form and strength of medicine	Doxycycline 100mg capsules Doxycycline 50mg capsules Doxycycline 100mg dispersible tablets
POM / P / GSL / ▼	POM
Dose	100mg
Route/Method	Orally
Frequency (To include maximum/minimum timescales)	Twice daily for seven days
Total dose/number	14
Total dose/number Drug interactions and action to be taken	All concurrent medications should be reviewed for interactions. A detailed list of all drug interactions is available in the BNF or the product SPC Drug interactions – If patients are taking the following medications they are excluded from the PGD and referred to Chalmers Centre or local sexual health service Isotretinoin Tretinoin /Retinoids Lithium Live cholera or typhoid vaccines Warfarin Atovaquone Carbamazepine Ergotamine and methysergide Ciclosporin Colestipol and colestyramine Methoxyflurane penicillins



PGD Number: 437 05 Version:

Cautions (including action to be taken if caution applies)	 Phenindione Phenytoin and fosphenytoin Phenobarbital Primidone Quinapril Rifampicin Strontium ranelate Sucralfate Sulphonylureas Doxycycline can cause photosensitivity resulting in skin reactions.
	 Patients must be cautioned to avoid sun exposure, sunbeds/lamps and to use appropriate protective measures such a sunblock, hats etc If photosensitivity occurs the patient should be advised
	to discontinue treatment and contact the NHS Lothian Sexual Health Service / LSRHS Local clinic for advice The absorption of doxycycline may be impaired by
	concurrently administered antacids or other drugs containing aluminium, calcium, magnesium zinc, iron, bismuth or kaolin. Dosages should be separated ideally by at least 2 before doxycycline or 6 hours after doxycycline
	• Giving iron 3 hours before or 2 to 3 hours after the tetracycline seems to avoid this interaction with most tetracyclines, although with doxycycline the interaction seems to occur to some extent even with a separation of 11 hours. (5) Patients who are taking regular/prescribed iron must seek advice from the prescriber/GP as to whether iron can be stopped temporarily during doxycycline treatment
	If visual disturbance occurs during treatment, prompt medical/ ophthalmologic evaluation is warranted, by contacting GP / Chalmers Centre or 111/NHS 24 if urgent
Adverse reactions and side effects including actions to be taken if adverse drug reaction is suspected (▼ - include yellow card details)	A detailed list of adverse reactions is available in the <u>SPC</u> and <u>BNF</u>
	Gastric upsets are common and include; abdominal pain, anorexia, nausea, vomiting*, diarrhoea*, dyspepsia and rarely dysphagia.
	* If patient is taking oral contraceptive pills and vomiting within 2 hours of taking the pill or severe diarrhoea occurs, follow advice as for missed pills. Refer to the most recent FSRH advice for directions to minimise the risk of contraceptive failure.



PGD Number: **437** Version: 05

	 If GI side effect not self-resolving, refer to patient's own GP Rarer side effects include: Clostridium difficile overgrowth, hepatotoxicity, pancreatitis, blood disorders, tinnitis, arthralgia and myalgia, rashes, photosensitivity, headaches, benign intracranial hypertension, visual disturbances and discoloration/enamel hypoplasia (usually on long-term use). Serious skin reactions, such as exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have been rarely reported in patients receiving doxycycline. If serious skin reactions occur, doxycycline should be discontinued immediately, and appropriate therapy should be instituted For the rarer side effects refer to a medical practitioner at the NHS Lothian Sexual Health Service / LSRHS Local Clinic Hypersensitivity reactions including anaphylaxis are rare- advise patient to call 999 if experiencing a hypersensitivity reaction Adverse drug reactions should be recorded in the patient's record If a serious adverse reaction is suspected please report to the MHRA/Commission on Human Medicines via theYellow Card Scheme http://yellowcard.mhra.gov.uk/
Additional advice and information	 Should be taken with fluids e.g. full glass of water in either a sitting or standing position Can be taken with milk or during meals to avoid gastric irritation. Second daily dose should be taken at least one hour before going to bed to avoid the risk of gastric irritation Advise to contact the NHS Lothian Sexual Health Service / local Clinic if condition worsens or symptoms develop Manufacturers Patient Information Leaflet should be given. Advise to abstain completely from sexual intercourse (even with condoms) including oral sex, during treatment and until treatment course completed and until partner(s) treatment completed. Advise to avoid exposure to direct sunlight or ultraviolet light including sunbeds/lamps .Patients who are unable/unwilling to take precautions against UV exposure should be referred to the Chalmers Centre to discuss alternative treatment options For any worsening advice please contact Chalmers Centre on 0131 536 1070 or 111/NHS 24 for urgent concerns



Referral, patient monitoring and follow-up	Return treatment voucher to the NHS Lothian Sexual Health Service with Pharmacy details to ensure cross referencing for payment and confirmation of voucher use
	Contact Chalmers Health Advisors team on 0131 536 2108/0131 536 1070 should there be questions or queries
	The individual should be advised to seek medical advice in the event of an adverse reaction.
Records	Complete and retain consultation form.
	A record of all individuals receiving treatment under this PGD should also be kept for audit purposes in accordance with local policy.
	See Record Audit Trail above

REFERENCES

- 1. BASHH Guidelines 2015 UK National guideline for the management of the infection of Chlamydia trachomatis last accessed 21/05/2025 via https://www.bashh.org/guidelines
- 2. BASHH Guidelines 2015 UK National guideline for the management of non-gonococcal urethritis last accessed 21/05/2025 via https://www.bashhguidelines.org/media/1051/ngu-2015.pdf
- 3. BNF Doxycycline last accessed via https://www.medicinescomplete.com on 21/05/2025
- 4. Doxycycline SmPC last accessed 03/12/2024 last updated 06/12/2021 via http://www.medicines.org.uk
- Medicines Complete (2025). Digital Medicines Information Suite. [online] MedicinesComplete. Available at: https://www.medicinescomplete.com/#/interactions/stockley.

PGD Number:

Version:

437

05